Format

Send to

Choose Destination
Future Oncol. 2015;11(3):409-20. doi: 10.2217/fon.14.290. Epub 2014 Dec 5.

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.

Author information

1
Department of Medicine (Lung), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.

Abstract

BACKGROUND:

Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents – other than docetaxel – that are approved second-line treatments for non-small-cell lung cancer.

METHODS:

The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.

RESULTS:

Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar.

CONCLUSION:

In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.

KEYWORDS:

NSCLC; adenocarcinoma; chemotherapy; nintedanib; second-line treatment

PMID:
25478720
DOI:
10.2217/fon.14.290
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center